Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Lxh254
1. Lxh254
2. 1800398-38-2
3. Lxh-254
4. Lxh254 Free Base
5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide
6. Pan-raf Inhibitor Lxh254
7. Naporafenib [inn]
8. 15jl80dg6h
9. 1800398-38-2 (free Base)
10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-
12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide
13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide
14. Lxh 254
15. K81
16. Unii-15jl80dg6h
17. Naporafenib [who-dd]
18. Chembl4583691
19. Lxh 254 [who-dd]
20. Schembl16094629
21. Bdbm88120
22. Gtpl10658
23. Bcp29080
24. Ex-a1846
25. Nsc807047
26. S8745
27. Akos037648965
28. At23218
29. Nsc-807047
30. Compound 15 [pmid: 31059256]
31. Ac-36207
32. Bl166445
33. Bs-16133
34. Hy-112089
35. Cs-0043317
36. Example 1156 [wo2014151616a1]
37. A16841
38. Us9694016, 1156
| Molecular Weight | 502.5 g/mol |
|---|---|
| Molecular Formula | C25H25F3N4O4 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 502.18278978 g/mol |
| Monoisotopic Mass | 502.18278978 g/mol |
| Topological Polar Surface Area | 96.8 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 709 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Naporafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naporafenib, including repackagers and relabelers. The FDA regulates Naporafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naporafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Naporafenib supplier is an individual or a company that provides Naporafenib active pharmaceutical ingredient (API) or Naporafenib finished formulations upon request. The Naporafenib suppliers may include Naporafenib API manufacturers, exporters, distributors and traders.
Naporafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naporafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naporafenib GMP manufacturer or Naporafenib GMP API supplier for your needs.
A Naporafenib CoA (Certificate of Analysis) is a formal document that attests to Naporafenib's compliance with Naporafenib specifications and serves as a tool for batch-level quality control.
Naporafenib CoA mostly includes findings from lab analyses of a specific batch. For each Naporafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naporafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Naporafenib EP), Naporafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naporafenib USP).
LOOKING FOR A SUPPLIER?
